Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flurbiprofen for Peri-Implant Mucositis Microbiome
NCT03090009Phase 1Unknown
- Start
- Apr 2017
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in peri-implant mucositis comparing Flurbiprofen with Placebo (2 arms). Primary endpoint: Change in the Microbiome at 28 days. Status: unknown.
02
Drugs
flurbiprofen
03
Conditions
peri-implant mucositis
Beyond the preview
Go deeper on NCT03090009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03090009.